Epidemiologic Analysis Along the Mevalonate Pathway Reveals Improved Cancer Survival in Patients Who Receive Statins Alone and in Combination With Bisphosphonates. El-Refai, S. M., Brown, J. D., Arnold, S. M., Black, E. P., Leggas, M., & Talbert, J. C. JCO Clinical Cancer Informatics, American Society of Clinical Oncology (ASCO), November, 2017.
Epidemiologic Analysis Along the Mevalonate Pathway Reveals Improved Cancer Survival in Patients Who Receive Statins Alone and in Combination With Bisphosphonates [link]Paper  doi  bibtex   
@article{ElRefai2017,
  doi = {10.1200/cci.17.00010},
  url = {https://doi.org/10.1200/cci.17.00010},
  year = {2017},
  month = nov,
  publisher = {American Society of Clinical Oncology ({ASCO})},
  number = {1},
  pages = {1--12},
  author = {Sherif M. El-Refai and Joshua D. Brown and Susanne M. Arnold and Esther P. Black and Markos Leggas and Jeffery C. Talbert},
  title = {Epidemiologic Analysis Along the Mevalonate Pathway Reveals Improved Cancer Survival in Patients Who Receive Statins Alone and in Combination With Bisphosphonates},
  journal = {{JCO} Clinical Cancer Informatics}
}

Downloads: 0